February 1, 2012

As part of DSN's Executive Retailer Viewpoint series, DSN sat down with Jason Reiser, VP health and wellness, ops/compliance at Sam's Club, at DSN's Industry Issues Summit to discuss how to better engage customers and the impact of the economy on business in 2012.

January 18, 2012

In an effort to tap into the minds of some of the industry's top executives, Drug Store News recently sat down and talked with some of these leaders in a multipart executive viewpoint video series.

July 10, 2014

A wave of new drug introductions and healthcare policy changes has had a significant impact on women’s health care over the past year.

July 10, 2014

While sales of heat and ice packs are relatively flat — the category generated slight growth of 0.2% to $235.9 million for the 52 weeks ended April 20 across total U.S. multi-outlets, according to IRI — there has been some positive momentum within the category.

July 8, 2014

Greenstone, a U.S.-based subsidiary of Pfizer, announced the introduction of doxazosin mesylate tablets.

June 30, 2014

Afrezza, an inhaled insulin powder meant to treat diabetes patients, was approved Friday by the Food and Drug Administration.

June 18, 2014

There’s a lot happening in the allergy space right now. Chattem’s Nasacort Allergy 24HR recently hit store shelves, and in a little more than 10 weeks on the shelf the nasal corticosteroid has already generated $33.6 million in sales across total U.S. multi-outlets, according to IRI.

June 9, 2014

Bayer last week named Dieter Weinand president of Bayer HealthCare Pharmaceuticals effective Aug. 1.

June 2, 2014

Mylan announced on Monday that it has entered into a settlement and license agreement with Pfizer relating to Mylan's abbreviated new drug application filed with the U.S. Food and Drug Administration for celecoxib capsules in 50-mg, 100-mg, 200-mg and 400-mg strengths.

May 30, 2014

Teva Pharmaceutical Industries announced on Friday that the U.S. District Court for the Northern District of West Virginia has denied a motion filed by Mylan and issued an opinion and order affirming a decision by the FDA under which Teva should receive sole 180-day “first-to-file” exclusivity for generic Celebrex (celecoxib) 100-, 200- and 400-mg capsules.

May 27, 2014

Pfizer on Tuesday announced the introduction in the United States of over-the-counter Nexium 24HR, making the "Purple Pill" available for the treatment of frequent heartburn in adults.

May 27, 2014

Pfizer on Monday reiterated that its bid on May 18 of $118 billion for AstraZeneca was the final offer on the table.

May 19, 2014

Pfizer on Sunday made a final offer valued at $118 billion for AstraZeneca. AstraZeneca, in turn, rejected the bid Monday morning.

May 16, 2014

Pfizer announced plans to submit a new drug application with the Food and Drug Administration for palbociclib, which is used for the first-line systemic treatment of post-menopausal women with advanced or metastatic breast cancer.

May 15, 2014

Greenstone announced the introduction of rifabutin capsules to its product line. The drug is the authorized generic version of Mycobutin.

May 15, 2014

The stampede of big-selling branded medicines that hurtled off the patent cliff in 2011 and 2012 has slowed to a relative trickle.

May 15, 2014

The VMS and diet aid/sports nutrition markets together command $11.9 billion in total retail sales, excluding specialty channels, and is growing at a steady clip.

May 15, 2014

With Pfizer's targeted takeover of AstraZeneca, there's been much talk about inversion, or the practice of re-domiciling a company's headquarters to another country in an effort to save on corporate taxes.

May 14, 2014

The American College of Physicians, CECity and Pfizer on Wednesday announced a new initiative designed to increase adult immunization rates.

May 13, 2014

Pfizer testified before British Parliament Tuesday regarding its proposed offer to acquire AstraZeneca, the New York Times reported.

May 6, 2014

Pfizer's Nexium 24HR will launch May 27, Pfizer reported in a conference call Monday.

May 2, 2014

AstraZeneca rejected Pfizer's $106 billion bid for the company Friday morning.

May 2, 2014

Pfizer early Friday morning upped the ante in its bid for AstraZeneca, which is now valued at $106 billion.

April 28, 2014

Mylan last week announced that it filed suit against the Food and Drug Administration, challenging the agency's decision regarding generic drug marketing exclusivity on celecoxib capsules, the generic equivalent of Pfizer's Celebrex.